Skip to main content
. 2020 Feb 6;48(6):2956–2968. doi: 10.1093/nar/gkaa065

Figure 4.

Figure 4.

PRMT5 maintains gene expression via blocking EZH2-mediated H3K27 methylation. (A) Molm13 cells were treated with DMSO, EZH2 inhibitor (1 µM) or PRMT5 inhibitor (1 µM) or combination of both inhibitors at 1 µM for 4 days. Heat maps show the differentially expressed coding genes at 2-fold cut-off. (B) Pathway analysis of PRMT5 inhibitor-induced up- and downregulated genes. (C) Venn diagrams show the overlaps of 2-fold downregulated genes between: left: PRMT5i-treated and PRMT5i/EZH2i combined treatment groups; Middle: EZH2i-treated and PRMT5i-treated groups. Right: overlap of 2-fold upregulated genes between PRMT5i-treated and PRMT5i/EZH2i combined treatment groups. (D) Two representative RNA-sequencing tracks showing that the PRMT5i upregulated gene is not affected by combined treatment of EZH2i; while the PRMT5i downregulated gene is partially restored by EZH2i. (E) Heat map shows the differentially expressed genes between PRMT5i-treated and PRMT5i and EZH2i combined treatment groups.